Syros Pharmaceuticals
Update in progressSYRS (OTC Markets OTCPK)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Syros Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for hematologic malignancies. Its lead candidates include Tamibarotene, a selective retinoic acid receptor alpha agonist in Phase III for genomically defined myelodysplastic syndrome subsets and Phase II for acute myeloid leukemia; SY-2101, an oral arsenic trioxide for acute promyelocytic leukemia; and SY-5609, a CDK7 inhibitor in Phase I for advanced solid tumors. Formerly LS22, Inc., it was renamed in 2012, was incorporated in 2011, and is headquartered in Cambridge, Massachusetts.
Company score
- Sentiment
- -0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.09
- Governance
- -0.06
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketOTC Markets OTCPK (PNK)
- LocationUnited States
- Founded2011
- Employees68
- Websitewww.syros.com
Identifiers
- ISINUS87184Q1076
- FIGIBBG004FFTL76
- LEI549300512PURS7IGVT96
- CUSIP87184Q107
- CIK0001556263